arrow
M

Makoto Nishio

cancer institute hospital of japanese foundation for cancer research
H指数:69
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

J-TAIL-2研究结果的简明摘要:一项关于日本广泛期小细胞肺癌患者接受阿替利珠单抗联合化疗长期随访的研究

2026-10-010
OA
Atezolizumab plus chemotherapy for Asian vs. non-Asian patients with extensive-stage small-cell lung cancer: A propensity score matched pooled analysis of four phase 3 trials

阿特朱单抗联合化疗用于亚洲与非亚洲广泛期小细胞肺癌患者的比较:一项基于四项III期临床试验的倾向性评分匹配合并分析

2026-09-270
OAAI
Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

塔拉他马布在铂类化疗后的小细胞肺癌中的应用:DeLLphi-304研究中日本患者的亚组分析

2026-09-190
OAAI
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

纳武利尤单抗联合伊匹木单抗为基础的治疗在日本转移性非小细胞肺癌患者(肿瘤PD-L1 < 1%)中的合并分析

2026-08-110
OA
Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

辅助阿来替尼与化疗在切除后的ALK阳性非小细胞肺癌(ALINA):一项随机、开放标签、III期试验的健康相关生活质量与安全性结果

2026-08-010
OAAI
Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study

度伐利尤单抗在不可切除III期非小细胞肺癌患者完成同步放化疗后发生2级放射性肺炎时的完成及重新给药:一项单中心真实世界研究

2026-07-270
OA
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study

依匹木单抗联合纳武利尤单抗,联合或不联合化疗,根据基线肿瘤大小评估其疗效:一项多中心回顾性研究

2026-06-300
PRE
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2

J-TAIL-2研究中接受阿替利珠单抗联合疗法治疗的肺癌患者血浆蛋白质组学分析用于生物标志物发现

2026-04-010
OAAI
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

阿特珠单抗治疗晚期NSCLC患者外周血T细胞谱及血浆蛋白质组学分析

2026-02-020
OAAI
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

Nivolumab联合化疗和贝伐单抗治疗TASUKI-52非鳞NSCLC患者的4年预后

2026-01-290
OAAI
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer

ALINA研究结果的大众语言摘要:alectinib与化疗相比,在ALK阳性非小细胞肺癌患者术后的应用

2025-12-310
PRE
Atezolizumab plus Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)

阿特珠单抗联合化疗治疗日本临床实践中晚期非小细胞肺癌(J-TAIL-2)

2025-12-010
OAAI
The first case of GOLGA5-RET fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib

头颈部GOLGA5-RET融合阳性恶性梭形细胞肉瘤对selpercatinib有反应的首例病例。

2025-09-010
PRE
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC

RELAY研究:雷莫芦单抗联合厄洛替尼在老年日本患者中针对转移性EGFR突变非小细胞肺癌的安全性与有效性

2025-09-010
PRE
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

免疫相关不良事件严重程度对接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者总生存期的影响,重点关注联合方案。

2025-06-010
OAAI
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer: Phase 3 LEAP-006 Study

仑伐替尼联合帕博利珠单抗、培美曲塞和铂类药物作为转移性非鳞状非小细胞肺癌的一线治疗方案:III期LEAP-006研究

2025-05-240
PREAI